Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Earnings for Alpine Immune Sciences, Inc. (ALPN)
Earnings in 2023 (TTM): $-32,081,000
According to Alpine Immune Sciences, Inc.'s latest financial reports the company's current earnings (TTM) are $-32,081,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Alpine Immune Sciences, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-32,081,000 | $-32,183,999 |
| 2022 | $-55,432,000 | $-57,762,000 |
| 2021 | $-50,420,000 | $-50,333,000 |
| 2020 | $-27,946,000 | $-27,940,000 |
| 2019 | $-41,852,000 | $-42,534,000 |
| 2018 | $-36,853,000 | $-36,487,000 |
| 2017 | $-7,983,000 | $-7,783,000 |
| 2016 | $-31,463,000 | $-31,463,000 |
| 2015 | $-22,818,000 | $-22,818,000 |
| 2014 | $-15,036,012 | $-15,036,012 |
| 2013 | $-16,198,000 | $-16,198,000 |
| 2012 | $-9,572,760 | $-9,572,760 |